A. Apathy B. Communication C. Motivation D. Socio-economic

A. Patient with type 1 diabetes who has atherosclerotic cardiovascular disease risk B. Patient with heart failure with reduced ejection fraction about to be discharged home C. Patient with chronic kidney disease with history of recurrent vulvovaginitis D. Patient with pre-diabetes and hyperlipidemia

A. SGLT2 inhibitors reduce cardiovascular and renal risk only in individuals with type 2 diabetes mellitus B. SGLT2 inhibitors reduce cardiovascular risk, but not renal risk in individuals with type 2 diabetes mellitus C. SGLT2 inhibitors reduce renal risk in individuals with and without type 2 diabetes mellitus status D. SGLT2 inhibitors reduce cardiovascular risk, but not renal risk in individuals with and without type 2 diabetes mellitus

A. eGFR typically declines by 10-20% after SGLT2 inhibitor initiation B. eGFR typically increases by 10-20% after SGLT2 inhibitor initiation C. The eGFR declines after SGLT2 inhibitor initiation is associated with an increased risk of end-stage kidney disease D. The eGFR increases after SGLT2 inhibitor initiation is associated with a decreased risk of end-stage kidney disease

A. Cardiorenal metabolic syndrome is a broad term that encompasses many different pathophysiologies, but highlights the important relationship between the kidneys and the heart as the 2 main organs that are involved in this process B. Cardiorenal metabolic syndrome includes cardiac or renal injury that starts in 1 organ and transfers to the other, in either direction C. Cardiorenal metabolic syndrome is more complicated than just hemodynamics, but also involves both neurohormonal and inflammatory systems D. All of the above statements are correct

A. Reduction and arrest of erythropoiesis at the kidney B. Inhibition of the sympathetic nervous system and reduction in cellular oxidative stress C. Reduction in diuresis/natriuresis and preservation of blood pressure D. Increase in cardiac remodeling and left ventricular ejection fraction